New research presented at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (12–15 May) and published in The Lancet shows that people who have lost weight using the maximum tolerated ...
ISTANBUL — Continuing tirzepatide helped adults without diabetes maintain far more of their initial weight loss than stopping the drug, with the strongest effect seen in those who stayed on their ...
NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and ...
By Nancy Lapid Aug 31 (Reuters) - People taking popular GLP-1 obesity drugs who remain on low starter doses will lose some ...
Researchers conducted a systematic review and meta-analysis to compare glycemia and weight loss outcomes between tirzepatide and semaglutide doses. High-dose tirzepatide (15 mg) was more effective for ...
Studies show tirzepatide leads to significantly more weight loss on average compared to semaglutide. Tirzepatide and semaglutide are both FDA-approved weekly injections for weight management and type ...
In SURMOUNT-MAINTAIN, participants switching to a 5mg maintenance dose of tirzepatide experienced a mean weight change of 5.6 kg over 52 weeks, following an initial 60-week weight-loss period. Oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results